Bone Abstracts

Introduction: Bisphosphonates are drugs of first choice in the treatment of postmenopausal osteoporosis; they inhibit bone resorbtion.Aim: This study evaluates the efficiency of bisphosphonates (alendronic acid+cholecalciferol 70 mg/5600 IU per weekly vs risedronic acid 35 mg/weekly vs ibandronic acid 150 mg/monthly) after 1 year of therapy.Methods: We present the results of a retrospective study which included 40 women with postme...

Introduction: The bone mineral density loss may be related to cancer. A specific correlation in the neuroendocrine tumors (NET) is not fully described yet.Aim: The analyze DXA in patients with or without NET.Material and method: We perfomed central DXA (spine and hip) with a GE Lunar device in post-menopausal women. None of them were previously treated with anti-osteoporotics drugs. The study groups included women with carcinoid tu...

Introduction: The FRAX model is a new method to assess fracture risk and this aspect is important in menopause. The DXA is still the golden standard but the relationship between these two instruments is complex.Aim: We correlate the 10-year absolute fracture risk of hip (10-yH) and major fractures (10-yM) based on FRAX with or without bone mineral density (BMD) with lumbar DXA in menopause women, and we use a statistical model to find out whether the vit...